期刊
CURRENT ONCOLOGY
卷 29, 期 5, 页码 3160-3170出版社
MDPI
DOI: 10.3390/curroncol29050257
关键词
gastroesophageal cancer; stomach cancer; esophageal cancer; gastroesophageal junction cancer; immunotherapy; checkpoint inhibitors
类别
资金
- Pfizer Canada Inc.
- Eisai Inc.
- IPSEN Biopharmaceutical Canada Inc.
- Viatris
- Taiho Pharma Canada Inc.
- Incyte Biosciences Canada
- Bristol-Myers Squibb Canada
- Amgen Canada Inc.
- AstraZeneca
Immunotherapy is increasingly recognized as playing an important role in the treatment of gastro-esophageal cancer, with experts from the Western Canadian Gastrointestinal Cancer Consensus Conference giving high attention to its role.
Gastric, esophageal and gastro-esophageal junction cancers are associated with inferior outcomes. For early-stage disease, perioperative chemotherapy or chemoradiation followed by surgery is the standard treatment. For most patients with advanced upper gastrointestinal tract cancers, platinum-based chemotherapy remains a standard treatment. Recently, several randomized clinical trials have demonstrated the benefit of immunotherapy involving checkpoint inhibitors alone or in combination with chemotherapy in patients with gastro-esophageal cancer and have changed the treatment landscape. The Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC), involving experts from four Western Canadian provinces, convened virtually on 16 June 2021 and developed the recommendations on the role of immunotherapy in patients with gastro-esophageal cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据